Dual PI3K and HDAC inhibitor, CUDC-907, effectively inhibits endometrial cancer growth <i>in vitro</i> and <i>in vivo</i>.

ABSTRACT:

Purpose

Hyperactivation of the PI3K/AKT/mTOR pathway promotes tumor progression in many cancers. Among these, endometrial cancer (EC) exhibits the highest frequency of alterations in this pathway, making it an ideal model for targeted treatment. Progestin therapy is initially effective, but advanced EC often resists treatment due to loss of progesterone receptor (PR) and acquired resistance. Furthermore, as obesity is the main etiological driver of EC, obesity-related factors activate the PI3K/AKT pathway and inhibit PR function. Therefore, there is a clinical need to identify therapies that enhance progestin sensitivity by upregulating PR, downregulating obesity-related factors, and inhibiting the PI3K/AKT pathway.

Methods

A dual HDAC (histone deacetylase) and PI3K inhibito

SUBMITTER: Zhang X 

PROVIDER: S-EPMC12623209 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature